JP2007167358A - Intraocular drug administration appliance - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an intraocular drug administration appliance solving problems with conventional pharmacological treatment using contact lens made of a hydrogel material, responding to many patients without any trouble caused by a long-time lens wearing such as oxygen deficit conditions of the cornea, and being advantageous in the price. <P>SOLUTION: A drug agent support appliance 1 has an annular or C-shaped plane formed of drug sustained-release hydrogel material incorporating a large quantity of drug and controllable of drug releasing speed. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to an intraocular drug administration device using a hydrogel material capable of sustained drug release capable of controlling the drug release rate.

  Conventionally, in ophthalmic medicine, eye drops are used from the viewpoint of easy handling and effectiveness in drug treatment for diseases such as dry eye, glaucoma, conjunctivitis or corneal epithelial disorder.

  However, eye drops administered into the eye are extremely difficult to keep in the eye for a long time by blinking the eyelids or replacing tears, and most of them (90% or more) are short-term. It is washed away by tears.

  Therefore, in order to increase the efficacy of eye drops, it is necessary to continue administration in a relatively short cycle, but frequent instillation is difficult at a certain time in patients, especially while sleep is reduced during sleep, A situation occurs where administration cannot be performed for a long time.

  Conversely, instillation beyond the prescription will lead to a decrease in tear components, which may cause adverse effects such as worsening of symptoms and corneal epithelial disorder, and absorption of excess drugs. It is not preferable because there may be side effects on the human body or disease.

  Therefore, for example, JP 2005-218780 A, JP 2005-314338 A, etc., contact lenses made of a hydrogel material capable of sustained drug release with a large drug uptake amount and capable of controlling the drug release rate. And an intraocular lens.

  Therefore, by using a contact lens made of the hydrogel material presented in the above publication, it is possible to control the drug release rate and to administer an appropriate amount of drug over a long period of time. Treatment can be expected.

However, the drug treatment is performed by long-term wearing of contact lenses. For this reason, there is a concern that the cornea may be damaged due to long-term wearing such as an oxygen-deficient state. In addition, there is a problem that a patient who is inadequate for contact lenses cannot be used.
JP 2005-218780 A JP 2005-314338 A

  The present invention has been made in view of the above circumstances, and solves the problem of drug treatment using a contact lens made of a conventional hydrogel material, and the cornea is damaged due to long-term wearing such as an oxygen-deficient state. Therefore, the present invention provides an intraocular drug administration device that can be applied to many patients without cost and is also advantageous in price.

  In order to solve the above-mentioned problems, the intraocular drug administration device of the present invention has a ring-shaped plane formed by a sustained-release drug hydrogel material that has a large amount of drug uptake and can control the drug release rate. In particular, it is preferable that the entire size is attachable to the conjunctival sac.

  Since the intraocular drug administration device according to the present invention has an annular shape, it is used by being almost entirely fitted in the conjunctival sac, so that it can be attached and removed easily by a doctor, and is particularly vacant in the central annular portion. Unlike the contact lens, the cornea is exposed, so the cornea is not deficient in oxygen and is not damaged by dry eye, dust, or germs. As a whole, the surface area is smaller than that of a contact lens, so that expensive material costs are low and the economy is excellent.

  Further, in the present invention, when the plane formed by the drug sustained-release hydrogel material having a large amount of drug uptake and capable of controlling the drug release rate has a C shape, it is outside of the annular shape. Since there is tolerance in the diameter and the inner diameter, it is easy to cope with the diameter of the conjunctival sac of the patient to be worn.

  Furthermore, in the present invention, when an inward protruding portion is formed on a part of the inner peripheral edge, the protruding portion can be grasped and attached to or removed from the conjunctival sac. Easy.

  According to the present invention, it is possible to administer an appropriate amount of a drug administered into the eye to the affected area over a long period of time, and a sufficient therapeutic effect can be expected. In addition, because it does not cover the surface of the cornea unlike a contact lens, there is no fear of corneal oxygen deficiency or various damage caused by wearing, and it can be used for patients who are inappropriate for wearing contact lenses. Easy and economical.

 Next, embodiments of the present invention will be described with reference to the drawings.

  FIG. 1 shows an intraocular drug administration device 1 according to the present invention. The drug administration device 1 has an annular shape as a whole. For example, JP 2005-218780 A, JP 2005-314338 A, and the like. As shown in the above, a contact lens made of a hydrogel material capable of sustained drug release, which has a large amount of drug uptake and can control the drug release rate, is manufactured in substantially the same manner using the same material.

Here, although detailed description thereof is omitted, for example, a target drug, a monomer having a specific functional group capable of forming a physical cross-linking structure with the target drug, and a cross-linking agent and satisfying the following formula (1) It consists of hydrogel material obtained by superposing | polymerizing a liquid mixture.
y ≦ 0.277x−10 (1)
(Here, x represents the molar concentration (mM) of the monomer having a specific functional group, and y represents the molar concentration (mM) of the target drug. However, x is 50 to 800.)
In addition, by applying surface modification to the hydrogel material, the amount of drug that can be incorporated is large, and a sufficient amount of drug to obtain a medicinal effect by greatly improving the amount of drug incorporated into the gel per unit volume. Can be obtained in the gel and the incorporated drug can be released slowly.

  The drug contained in the hydrogel material capable of controlled drug release that can control the drug release rate includes antibiotics, antiviral agents, anti-inflammatory agents, steroids, peptides, polypeptides, antiallergic agents, α-adrenergic blocking. Agents, β-adrenergic blockers, anti-cataract agents, glaucoma therapeutic agents, ophthalmic agents, lacrimal secretion enhancers, local or partial anesthetics of the eye and the like.

  Further, in the present embodiment, the whole has a thin plate shape like a contact lens, and the overall size is a conjunctiva formed between the eyelid 3 and the eyeball 4 in the eye socket 2 of the human body shown in FIG. The size is fitted into the sac 5.

  The drug administration device 1 according to the present embodiment configured as described above is used by being fitted into the conjunctival sac 5 as shown in FIG. An appropriate amount of drug is thus released into the eye over a long period of time from the drug administration device 1 fitted in the conjunctival sac 5.

  At this time, since the drug administration device 1 of the present invention does not touch the cornea 6, there is no feeling of wearing the contact lens, and the contact lens due to lack of oxygen or contamination of the cornea 6 is not used. Not only does it cause discomfort due to wearing, but long-term wearing does not cause any problems.

  In addition, although the case where the medicine administration device 1 in this Embodiment was circular as a whole was shown, it does not necessarily need to be circular, for example, an appropriate horizontally long ellipse may be used (not shown). In the case of a horizontally long oval shape, a part of the cornea sac is fitted into the conjunctival sac 5 so that it is easy to attach and detach, and a part directly contacts the cornea 6 part. It is suitable for direct administration.

  Further, FIG. 4 shows a different embodiment of the present invention, and the material and the overall configuration are almost the same as those of the embodiment shown in FIG. 1, but the whole has a C shape in a plane. The point is different.

  Since the present embodiment has a C shape as a whole in a plane, it can be sized by expanding and contracting the free end portion even when the diameters do not match somewhat when attached to the conjunctival sac 5 shown in FIG. It is possible to attach to different conjunctival sac 5 and is excellent in versatility, and it is economical because it is not necessary to prepare many different diameters according to the size of each patient's conjunctival sac. .

  Furthermore, what is shown in FIG. 5 shows a further different embodiment of the present invention, in that an inward protruding portion 12 is formed on a part of the inner peripheral edge 11 of the drug support 1. Different. In the present embodiment, the work can be easily performed by gripping the protruding portion 12 with an operation tool such as tweezers for contact lenses at the time of mounting and dismounting. Moreover, since the protrusion 12 contacts with the corneal portion at the time of wearing (not shown), a direct administration effect of the drug to the cornea can be expected.

  Each of the above embodiments has the advantage that it is easy to wear and less burden on the eyes because it is formed in a thin plate shape like a contact lens, but the present invention has a circular cross section. This may be present (not shown). In this case, the cross-sectional area is increased, so that the amount of the drug taken up can be increased, and there is an advantage that administration for a long time is prolonged.

The top view which shows preferable embodiment of this invention. The cross-sectional schematic of the eye socket of a human body. Explanatory drawing which shows the use condition of embodiment shown in FIG. The top view which shows different embodiment of this invention. The top view which shows further another embodiment of this invention.

Explanation of symbols

DESCRIPTION OF SYMBOLS 1 Drug support body, 2 Orbit part, 3 Eyelid, 4 Eyeball, 5 Conjunctival sac, 11 Inner periphery, 12 Protrusion part

Claims (4)

  An intraocular drug administration device characterized in that a plane formed by a drug sustained-release hydrogel material having a large amount of drug uptake and capable of controlling the drug release rate has an annular shape.   An intraocular drug administration device in which a plane formed by a drug sustained-release hydrogel material having a large amount of drug uptake and capable of controlling the drug release rate has a C shape.   The intraocular drug administration device according to claim 1 or 2, wherein an inward projection is formed at a part of the inner peripheral edge. 4. The intraocular drug administration device according to claim 1, 2 or 3, wherein the entire size is attachable to the conjunctival sac.

Images